NAMPT Inhibitors

Table Of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION
2.1. Overview of NAMPT Inhibitors
2.2. Key Historical Events Related to NAMPT Inhibitors
2.3. NAMPT Inhibitors: Recent Activity
2.4. NAMPT Inhibitors: Mechanism of Action
2.5. NAMPT Inhibitors: Key Target Indications

3. MARKET LANDSCAPE
3.1. NAMPT Inhibitors: Pipeline Review
3.1.1. Analysis by Phase of Development
3.1.2. Analysis by Type of Molecule
3.1.3. Analysis by Phase of Development and Type of Molecule
3.1.4. Analysis by Type of Therapy
3.1.5. Analysis by Line of Treatment
3.1.5. Analysis by Route of Administration

3.2. NAMPT Inhibitors: Developer Landscape
3.2.1. Analysis by Type of Player
3.2.2. Analysis by Year of Establishment
3.2.3. Analysis by Location of Headquarters
3.2.4. Analysis by Location of Headquarters and Stage of Development
3.2.5. Analysis by Location of Headquarters and Phase of Development
3.2.6. Analysis by Location of Headquarters and Type of Molecule

4. PARTNERSHIPS AND COLLABORATIONS
4.1. NAMPT Inhibitors: Partnerships and Collaborations
4.1.1. Analysis by Year of Partnership
4.1.2. Analysis by Type of Partnership
4.1.3. Analysis by Year and Type of Partnership
4.1.4. Analysis by Type of Agreement
4.1.5. Analysis by Intercontinental and Intracontinental Deals
4.1.6. Active Players: Analysis by Number of Partnerships

5. FUNDING AND INVESTMENTS
5.1. NAMPT Inhibitors: Funding and Investments
5.1.1. Analysis of Instances by Year
5.1.2. Analysis of Amount Raised by Year
5.1.3. Analysis of Number of Instances Year and Type of Funding
5.1.4. Analysis of Amount Raised by Year and Type of Funding
5.1.5. Analysis of Number of Instances by Type of Funding
5.1.6. Analysis of Amount Raised by Type of Funding
5.1.7. Most Active Investors: Analysis by Number of Funding Instances

5.1.8. Active Players: Analysis by Number of Instances
5.1.9. Active Players: Analysis by Amount Raised
5.1.10. Analysis of Instances by Geography
5.1.11. Analysis of Total Amount Raised by Geography
5.1.12. Analysis of Total Amount Raised by Year of Establishment
5.1.13. Concluding Remarks

6. GRANTS ANALYSIS
6.1. Scope and Methodology
6.2. NAMPT Inhibitors: List of Grants Awarded by National Institutes of Health
6.2.1. Analysis of Instances by Year
6.2.2. Analysis of Amount Awarded by Year
6.2.3. Popular Recipient Organizations: Analysis by Grant Amount
6.2.4. Prominent Program Officers: Analysis by Number of Grants
6.2.5. Analysis by Type of Recipient Organization
6.2.6. Analysis of Instances by Year
6.2.7. Analysis by Purpose of Grant Award
6.2.8. Analysis by Funding Institute
6.2.9. Analysis by Support Period
6.2.10. Analysis by Funding Institute and Support Period
6.2.11. Analysis by Activity Code
6.2.12. Analysis by Type of Application
6.2.13. Word Cloud of NIH Spending Categories

7. COMPANY COMPETITIVENESS
7.1. Key Assumptions and Parameters
7.2. Methodology
7.3. Benchmarking of Portfolio Strength
7.4. Benchmarking of Partnership Activity
7.5. Benchmarking of Funding Activity
7.6. Benchmarking of Portfolio Strength
7.7. NAMPT Inhibitors: Company Competitiveness Analysis

8. COMPANY PROFILES
8.1. Antengene Therapeutics
8.1.1. Company Overview
8.1.2. Funding Information
8.1.3. Product Portfolio
8.1.4. Recent Developments and Future Outlook

8.2. Aqualung Therapeutics
8.2.1. Company Overview
8.2.2. Funding Information
8.2.3. Product Portfolio
8.2.4. Patent Portfolio
8.2.5. Recent Developments and Future Outlook

8.3. Karyopharm Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.4. Patent Portfolio
8.3.5. Recent Developments and Future Outlook

8.4. OncoTartis
8.4.1. Company Overview
8.4.2. Funding Information
8.4.3. Product Portfolio
8.4.4. Patent Portfolio
8.4.5. Recent Developments and Future Outlook

8.5. Onxeo
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Product Portfolio
8.5.4. Recent Developments and Future Outlook

9. PUBLICATION ANALYSIS
9.1. Methodology and Key Parameters
9.2. NAMPT Inhibitors: List of Publications
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Most Popular Journals: Analysis by Number of Publications
9.2.4. Most Popular Publishers: Analysis by Number of Publications
9.2.5. Analysis by Journal Impact Factor
9.2.6. Most Popular Journals: Analysis by Journal Impact Factor
9.2.7. Analysis by Geography
9.2.8. Emerging Focus Areas

10. GLOBAL EVENTS ANALYSIS
10.1. Methodology and Key Parameters
10.2. NAMPT Inhibitors: List of Global Events
10.2.2. Cumulative Year-wise Trend
10.2.3. Analysis by Type of Event
10.2.4. Analysis by Event Platform
10.2.5. Leading Players: Analysis by Number of Participants
10.2.6. Leading Presenters: Analysis by Number of Participants
10.2.7. Analysis by Geography

11. SOCIAL MEDIA ANALYSIS
11.1. Methodology and Key Parameters
11.1.1. Cumulative Year-wise Activity
11.1.2. Leading Users: Analysis by Number of Tweets
11.1.3. Trending Words / Phrases on Twitter

12. DRUG FAILURE ANALYSIS
12.1. Methodology and Key Parameters
12.2. NAMPT Inhibitors: List of Failed Drug Candidates
12.2.1. Analysis by Phase of Discontinuation
12.2.2. Analysis by Trial Status
12.2.3. Analysis by Target Indication
12.2.4. Analysis by Route of Administration
12.2.5. Analysis by Type of Sponsor
12.2.6. Affiliated Stakeholders: Analysis by Number of Trials
12.2.7. Analysis by Reasons for Drug Failure
12.2.8. Key Terms in Study Results
12.2.9. Other Plausible Reasons for Drug Failure

13. FDA APPROVAL STRATEGIES
13.1. Methodology and Key Parameters
13.2. General Reasons for Failure of Trials Focused on NAMPT Inhibitors and Key Strategies Adopted by Developers
13.3. Drug Specific Business Models followed by Company
13.4. Analysis of Drug Candidates by Business Model

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Key Assumptions and Parameters
14.2. Forecast Methodology
14.3. Global NAMPT Inhibitors Market, 2027-2040
14.4. List of Forecasted Drugs
14.4.1. OT-82, OncoTartis
14.4.1.1. Global Sales Forecast
14.4.1.2. Regional Sales Forecast
14.4.1.3. Net Present Value
14.4.1.4. Value Creation Analysis

14.4.2. ALT-100, Aqualung Therapeutics
14.4.2.1. Global Sales Forecast
14.4.2.2. Regional Sales Forecast
14.4.2.3. Net Present Value
14.4.2.4. Value Creation Analysis

14.4.3. ATG-019, Antengene Therapeutics
14.4.3.1. Global Sales Forecast
14.4.3.2. Regional Sales Forecast
14.4.3.3. Net Present Value
14.4.3.4. Value Creation Analysis

14.4.4. KPT-9274, Karyopharm Therapeutics
14.4.4.1. Global Sales Forecast
14.4.4.2. Regional Sales Forecast
14.4.4.3. Net Present Value
14.4.4.4. Value Creation Analysis

14.5. NAMPT Inhibitors Market: Analysis by Type of Molecule, 2027 and 2040
14.5.1. NAMPT Inhibitors Market for Small Molecules, 2027-2040
14.5.2. NAMPT Inhibitors Market for Biologics, 2029-2040

14.6. NAMPT Inhibitors Market: Analysis by Therapeutic Area, 2027 and 2040
14.6.1. NAMPT Inhibitors Market for Oncological Disorders, 2027-2040
14.6.2. NAMPT Inhibitors Market for Respiratory Disorders, 2029-2040

14.7. NAMPT Inhibitors Market: Analysis by Target Indication, 2027 and 2040
14.7.1. NAMPT Inhibitors Market for Non-Hodgkin Lymphoma, 2027-2040
14.7.2. NAMPT Inhibitors Market for Hodgkin Lymphoma, 2027-2040
14.7.3. NAMPT Inhibitors Market for Acute Respiratory Distress Syndrome, 2029-2040
14.7.4. NAMPT Inhibitors Market for Acute Myeloid Leukemia, 2033-2040

14.8. NAMPT Inhibitors Market: Analysis by Line of Treatment, 2027 and 2040
14.8.1. NAMPT Inhibitors Market for First Line Therapies, 2027-2040
14.8.2. NAMPT Inhibitors Market for Second Line Therapies, 2033-2040

14.9. NAMPT Inhibitors Market: Analysis by Route of Administration, 2027 and 2040
14.9.1. NAMPT Inhibitors Market for Oral Therapies, 2027-2040
14.9.2. NAMPT Inhibitors Market for Intravenous Therapies, 2029-2040

14.10. NAMPT Inhibitors: Market Share of Key Players
14.11. NAMPT Inhibitors Market: Analysis by Geography, 2030-2040

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: LIST OF FIGURES

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Distribution by Phase of Development
Figure 3.2 Distribution by Type of Molecule
Figure 3.3 Distribution by Phase of Development and Type of Molecule
Figure 3.4 Distribution by Type of Therapy
Figure 3.5 Distribution by Line of Treatment
Figure 3.6 Distribution by Route of Administration
Figure 3.7 Distribution by Type of Player
Figure 3.8 Distribution by Year of Establishment
Figure 3.9 Distribution by Company Size
Figure 3.10 Players in North America
Figure 3.11 Players in Europe
Figure 3.12 Players in Rest of the World
Figure 3.13 Distribution by Stage of Development and Location of Headquarters
Figure 3.14 Distribution by Type of Molecule and Location of Headquarters
Figure 3.15 Distribution by Phase of Development and Location of Headquarters
Figure 4.1 Distribution by Year of Partnership
Figure 4.2 Distribution by Type of Partnership
Figure 4.3 Distribution by Year and Type of Partnership
Figure 4.4 Distribution by Type of Agreement
Figure 4.5 Distribution by Intercontinental and Intracontinental Deals
Figure 4.6 Distribution by Number of Partnerships
Figure 5.1 Distribution by Annual Instances
Figure 5.2 Distribution of Amount Invested by Year
Figure 5.3 Year-wise Distribution of Instances by Type of Funding
Figure 5.4 Year-wise Distribution of Amount Received and Type of Funding
Figure 5.5 Distribution of Instances by Type of Funding
Figure 5.6 Distribution of Amount Raised by Type of Funding
Figure 5.7 Most Active Investors by Number of Instances
Figure 5.8. Distribution by Number of Instances
Figure 5.9 Distribution by Amount Received
Figure 5.10 Distribution of Amount Raised by Geography
Figure 5.11 Distribution of Amount Raised by Year of Establishment
Figure 5.12 Concluding Remarks
Figure 6.1 Distribution of Grants by Year
Figure 6.2 Distribution of Amount Awarded by Year
Figure 6.3 Key Organizations by Amount Received
Figure 6.4 Distribution by Program Officers
Figure 6.5 Type of Recipient Organization
Figure 6.6 Distribution of Grants by Purpose of Award
Figure 6.7 Distribution by Funding Institute
Figure 6.8 Distribution by Support Period
Figure 6.9 Distribution by Funding Institute and Support Period
Figure 6.10 Distribution by Grant Activity Code
Figure 6.11 Distribution by Type of Application
Figure 6.12 Word Cloud of NIH Spending Categories
Figure 7.1 Benchmarking by Prominent Players
Figure 7.2 Distribution of Developers
Figure 9.1 Distribution of Year of Publication
Figure 9.2 Distribution of Type of Publication
Figure 9.3 Most Popular Journals
Figure 9.4 Most Popular Publisher
Figure 9.5 Distribution by Journal Impact Factor
Figure 9.6 Key Journals by Impact Factor
Figure 9.7 Geographical Distribution of Affiliated Organizations
Figure 9.8 Emerging Focus Areas
Figure 10.1 Cumulative Year-wise Trend of Global Events
Figure 10.2 Distribution by Type of Event
Figure 10.3 Distribution by Type of Platform
Figure 10.4 Leading Players by Number of Participations
Figure 10.5 Leading Presenters by Number of Participations
Figure 10.6 Geographical Distribution of Events
Figure 11.1 Cumulative Year-wise Trend of Tweets
Figure 11.2 Leading Users by Number of Tweets
Figure 11.3 Trending Words / Phrases on Twitter
Figure 12.1 Distribution by Phase of Discontinuation
Figure 12.2 Distribution by Trial Status
Figure 12.3 Distribution by Target Indication
Figure 12.4 Distribution by Route of Administration
Figure 12.5 Distribution by Type of Sponsor
Figure 12.6 Distribution by Affiliated Stakeholders
Figure 12.7 Distribution by Reason for Drug Failure
Figure 12.8 Key Terms in Study Results
Figure 12.9 Other Plausible Reasons for Drug Failure
Figure 14.1 Global NAMPT Inhibitors Market, 2027-2040
Figure 14.2 OT-82: Global Sales Forecast, 2027-2040
Figure 14.3 OT-82: Regional Sales Forecast, 2027-2040
Figure 14.4 ALT-100: Global Sales Forecast, 2029-2040
Figure 14.5 ALT-100: Regional Sales Forecast, 2029-2040
Figure 14.6 ATG-019: Global Sales Forecast, 2030-2040
Figure 14.7 ATG-019: Regional Sales Forecast, 2030-2040
Figure 14.8 KPT-9274: Global Sales Forecast, 2033-2040
Figure 14.9 KPT-9274: Regional Sales Forecast, 2033-2040
Figure 14.10 Distribution by Type of Molecule, 2027-2040
Figure 14.11 Small Molecules: Regional Sales Forecast, 2027-2040
Figure 14.12 Biologics: Regional Sales Forecast, 2029-2040
Figure 14.13 Distribution by Therapeutic Area, 2027-2040
Figure 14.14 Oncological Disorders: Regional Sales Forecast, 2027-2040
Figure 14.15 Respiratory Disorders: Regional Sales Forecast, 2029-2040
Figure 14.16 Distribution by Therapeutic Area, 2027-2040
Figure 14.17 NHL: Regional Sales Forecast, 2027-2035
Figure 14.18 Hodgkin Lymphoma: Regional Sales Forecast, 2027-2040
Figure 14.19 ARDS: Regional Sales Forecast, 2029-2040
Figure 14.20 AML: Regional Sales Forecast, 2033-2040
Figure 14.21 Distribution by Line of Treatment, 2027-2040
Figure 14.22 1st Line Therapies: Regional Sales Forecast, 2027-2040
Figure 14.23 2nd Line Therapies: Regional Sales Forecast, 2033-2040
Figure 14.24 Distribution by Route of Administration, 2027-2040
Figure 14.25 Oral Therapies: Regional Sales Forecast, 2027-20401
Figure 14.26 Intravenous Therapies: Regional Sales Forecast, 2029-2040
Figure 14.27 Market Share of Key Players
Figure 14.28 Distribution by Geography, 2030 and 2040

List Of Tables

Table 3.1 List of Drug Candidates
Table 3.2 List of Drug Developers
Table 4.1 NAMPT Inhibitors: Partnerships and Collaborations
Table 5.1 NAMPT Inhibitors: Funding and Investment
Table 6.1 List of Grants
Table 8.1 Antengene: Funding Information (USD Million)
Table 8.2 Antengene: Product Portfolio
Table 8.3 Antengene: Recent Developments
Table 8.4 Aqualung Therapeutics: Funding Information (USD Million)
Table 8.5 Aqualung Therapeutics: Product Portfolio
Table 8.6 Aqualung Therapeutics: Patent Portfolio
Table 8.7 Aqualung Therapeutics: Recent Developments
Table 8.8 Karyopharm Therapeutics: Financial Information (USD Million)
Table 8.9 Karyopharm Therapeutics: Product Portfolio
Table 8.10 Karyopharm Therapeutics: Patent Portfolio
Table 8.11 Karyopharm Therapeutics: Recent Developments
Table 8.12 OncoTartis: Funding Information (USD Million)
Table 8.13 OncoTartis: Product Portfolio
Table 8.14 OncoTartis: Patent Portfolio
Table 8.15 Onxeo: Financial Information (EUR Million)
Table 8.16 Onxeo: Product Portfolio
Table 8.17 Onxeo: Recent Developments
Table 9.1 NAMPT Inhibitors: List of Publications
Table 10.1 NAMPT Inhibitors: List of Global Events
Table 12.1 NAMPT Inhibitors: List of Failed Drug Candidates
Table 14.1 OT-82: Net Present Value, 2027-2040
Table 14.2 OT-82: Value Creation Analysis, 2027-2040
Table 14.3 ALT-100: Net Present Value, 2029-2040
Table 14.4 ALT-100: Value Creation Analysis, 2029-2040
Table 14.5 ATG-019: Net Present Value, 2030-2040
Table 14.6 ATG-019: Value Creation Analysis, 2030-2040
Table 14.7 KPT-9274: Net Present Value, 2033-2040
Table 14.8 KPT-9274: Value Creation Analysis, 2033-2040

List Of Companies

The following companies and organizations have been mentioned in the report:

1. 2M Companies
2. AbbVie
3. Allakos
4. Antengene   
5. Aqualung Therapeutics
6. Aravive
7. Aurigene
8. BioAlliance Pharma
9. Bioprocess Capital Partners
10. Boyu Capital
11. Bpifrance
12. Calico Life Sciences
13. Celgene (Acquired by Bristol-Myers Squibb)
14. Children’s Cancer Institute
15. Chione
16. Delphi Ventures
17. Eli Lilly
18. Epizyme
19. European Organization for Research and Treatment of Cancer
20. Fidelity Management & Research
21. Financière de la Montagne
22. Florida International University
23. Foresite Capital
24. FountainVest Partners
25. Fukuoka University
26. Gemin X (Acquired by Teva Pharmaceuticals)
27. GIC
28. Gossamer Bio
29. GSK
30. Gustave Roussy
31. HG
32. Hillhouse
33. Indiana University–Purdue University Indianapolis
34. Invus Public Equities Advisors
35. Ipsen
36. Johns Hopkins University
37. JSR Life Sciences
38. Karmanos Cancer Institute
39. Karyopharm Therapeutics 
40. LeaderMed p
41. Massachusetts General Hospital
42. Multiple Myeloma Research Foundation
43. National Institutes of Health
44. National Cancer Institute
45. New Leaf Venture Partners
46. Newcastle Hospitals
47. National Heart, Lung, and Blood Institute
48. National Institute of Aging
49. National Institute of Diabetes and Digestive and Kidney Diseases
50. National Institute of Neurological Disorders and Stroke
51. Norma Investments
52. Northern Centre for Cancer Care
53. Novartis
54. Ohio State University
55. OncoTartis
56. Onxeo
57. Paris-Sud University
58. Pharmstandard International
59. Qiming Venture Partners
60. Robert Wood Johnson Medical School
61. Rubius Therapeutics
62. Samuel Oschin Cancer Center
63. Sanofi
64. Seattle Genetics
65. Stanford University Medical School
66. Taikang Insurance Group
67. TF Capital
68. Tigermed
69. TopoTarget
70. Tufts University
71. University of Arizona
72. University of California Los Angeles
73. University of Illinois Chicago
74. University of Missouri
75. University of Pennsylvania
76. University of South Florida
77. University of Southern California
78. University of Turin
79. University of Toulouse
80. University of Utah
81. University of Wisconsin-Madison
82. US Oncology Network
83. UT Southwestern
84. Valo Health
85. Veterans Health Administration
86. Washington University
87. Wayne State University
88. WuXi Corporate Venture Fund
89. Yale University